We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00343785
Recruitment Status : Completed
First Posted : June 23, 2006
Results First Posted : March 16, 2017
Last Update Posted : April 13, 2017
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Rainer Storb, Fred Hutchinson Cancer Center

Brief Summary:
This clinical trial is studying how well giving cyclophosphamide together with anti-thymocyte globulin followed by methotrexate and cyclosporine works in preventing chronic graft-vs-host disease (GVHD) in patients with severe aplastic anemia undergoing donor bone marrow transplant. Giving low doses of chemotherapy, such as cyclophosphamide, before a donor bone marrow transplant helps stop the growth of abnormal cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining abnormal cells. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving anti-thymocyte globulin before and methotrexate and cyclosporine after transplant may stop this from happening

Condition or disease Intervention/treatment Phase
Aplastic Anemia Drug: cyclophosphamide Biological: anti-thymocyte globulin Drug: cyclosporine Procedure: allogeneic bone marrow transplantation Drug: methotrexate Genetic: DNA analysis Other: flow cytometry Genetic: polymorphism analysis Other: laboratory biomarker analysis Phase 2

Detailed Description:


I. Minimize the incidence of chronic GVHD by restricting the transplanted marrow dose to 2.0-2.5 x 10^8 nucleated cells/kg.


I. Engraftment and overall survival.


CONDITIONING REGIMEN: Patients receive cyclophosphamide intravenously (IV) on days -5 to -2 and anti-thymocyte globulin IV over 4-10 hours on days -4 to -2.

TRANSPLANTATION: Patients undergo allogeneic bone marrow transplantation on day 0.

GVHD PROPHYLAXIS: Patients receive methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV over 1 hour or orally (PO) twice daily on days -1 to 50, followed by a taper until 6 months after grafting.

After completion of study treatment, patients are followed up at on day 180, 1 year, 1.5 years, 2 years, 3 years, and yearly thereafter.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cyclophosphamide and Antithymocyte Globulin Conditioning Regimen for Marrow Transplantation From HLA-Matched Family Members for Severe Aplastic Anemia: Effect of Marrow Cell Dose on Chronic Graft-vs.-Host Disease: A Multi-Center Trial
Study Start Date : February 2006
Actual Primary Completion Date : May 2012
Actual Study Completion Date : August 2012

Arm Intervention/treatment
Experimental: Treatment (conditioning regimen, transplant, GVHD prophylaxis)
Patients receive a conditioning regimen comprising cyclophosphamide IV on days -5 to -2 and anti-thymocyte globulin IV over 4-10 hours on days -4 to -2. Patients undergo allogeneic bone marrow transplantation on day 0. Patients then receive GVHD prophylaxis comprising methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV over 1 hour or PO twice daily on days -1 to 50, followed by a taper until 6 months after grafting.
Drug: cyclophosphamide
Given IV
Other Names:
  • CPM
  • CTX
  • Cytoxan
  • Endoxan
  • Endoxana

Biological: anti-thymocyte globulin
Given IV
Other Names:
  • ATG
  • lymphocyte immune globulin
  • Thymoglobulin

Drug: cyclosporine
Given IV or PO
Other Names:
  • ciclosporin
  • cyclosporin
  • cyclosporin A
  • CYSP
  • Sandimmune

Procedure: allogeneic bone marrow transplantation
Undergo allogeneic bone marrow transplantation
Other Names:
  • bone marrow therapy, allogeneic
  • bone marrow therapy, allogenic
  • transplantation, allogeneic bone marrow
  • transplantation, allogenic bone marrow

Drug: methotrexate
Given IV
Other Names:
  • amethopterin
  • Folex
  • methylaminopterin
  • Mexate
  • MTX

Genetic: DNA analysis
Correlative studies

Other: flow cytometry
Correlative studies

Genetic: polymorphism analysis
Correlative studies

Other: laboratory biomarker analysis
Correlative studies

Primary Outcome Measures :
  1. Incidence of Chronic GVHD [ Time Frame: 2 years ]
    Analyzed using cumulative incidence estimates, treating death or rejection as competing risk events.

Secondary Outcome Measures :
  1. Number of Days to Neutrophil Recovery to >500/uL [ Time Frame: 100 days post-transplant ]
    First of 3 consecutive days of neutrophils >500/uL

  2. Overall Survival [ Time Frame: From the time of enrollment until death from any cause up to one year ]
    Number of patients alive at one year

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Any patient who has aplastic anemia with marrow failure involving 2 of the three following criteria: granulocytes < 500/uL; a corrected reticulocyte count of < 1%; platelet count of < 20,000/uL
  • Availability of an human leukocyte antigen (HLA)-matched family member
  • DONOR: Family member who is HLA-matched
  • DONOR: If more than one HLA-matched family member is available, priority will be given to a donor who is genotypically HLA-identical, of appropriate cytomegalovirus (CMV) serology, ABO compatible, and, in case of a female donor, non-parous

Exclusion Criteria:

  • Severe disease other than aplastic anemia that would severely limit the probability of survival during the graft procedure:

    • Patients who have developed clonal cytogenetic abnormalities or myelodysplastic syndrome (preleukemia)
    • Patients with Fanconi's anemia
    • Aplasia secondary to radiation or cytotoxic chemotherapy
    • Patients with paroxysmal nocturnal hemoglobinuria who have not developed aplastic anemia
  • Severe organ toxicities:

    • Cardiac insufficiency requiring treatment or symptomatic coronary artery disease;
    • Severe hypoxemia , partial pressure of oxygen (pO2) < 70 mm Hg, with decreased diffusion capacity of carbon monoxide (DLCO) < 70% of predicted; or mild hypoxemia, pO2 < 80 mm Hg with severely decreased DLCO < 60% of predicted;
    • Impaired renal function (creatinine > 2 times upper limit of normal or estimated creatinine clearance < 60 ml/min)
  • Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month
  • Human immunodeficiency virus (HIV)-positive patients
  • Females who are pregnant or breast-feeding
  • DONOR: Donors who have increase anesthetic risk and are not able psychologically and medically to tolerate the procedure
  • DONOR: HIV-positive donors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00343785

Layout table for location information
United States, Utah
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States, 84112
United States, Washington
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
United States, Wisconsin
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Sponsors and Collaborators
Fred Hutchinson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
Principal Investigator: Rainer Storb Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Layout table for additonal information
Responsible Party: Rainer Storb, Principal Investigator, Fred Hutchinson Cancer Center
ClinicalTrials.gov Identifier: NCT00343785    
Other Study ID Numbers: 2054.00
NCI-2010-01781 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
P01HL036444 ( U.S. NIH Grant/Contract )
First Posted: June 23, 2006    Key Record Dates
Results First Posted: March 16, 2017
Last Update Posted: April 13, 2017
Last Verified: March 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Aplastic
Hematologic Diseases
Bone Marrow Failure Disorders
Bone Marrow Diseases
Antilymphocyte Serum
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Antimetabolites, Antineoplastic
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors